Alcresta Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.1M
Doctors Paid
1,370
Transactions
2,644
2024 Total
$170,172
Payment Breakdown by Category
Research$1.4M (43.0%)
Consulting$769,760 (24.5%)
Food & Beverage$110,936 (3.5%)
Travel$55,531 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 46 | 43.0% |
| Consulting Fee | $769,760 | 58 | 24.5% |
| Current or prospective ownership or investment interest | $332,034 | 2 | 10.6% |
| Honoraria | $174,801 | 71 | 5.6% |
| Space rental or facility fees (teaching hospital only) | $120,498 | 68 | 3.8% |
| Food and Beverage | $110,936 | 2,130 | 3.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $95,500 | 38 | 3.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $94,250 | 35 | 3.0% |
| Travel and Lodging | $55,531 | 182 | 1.8% |
| Grant | $13,020 | 2 | 0.4% |
| Education | $11,768 | 9 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,250 | 3 | 0.4% |
Payments by Type
General
$1.8M
2,598 transactions
Research
$1.4M
46 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 90 Day Observational Study as an Extension to the Phase 3, Open Labeled, Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition | $624,668 | 0 | 1 |
| General Research relating to application of RELiZORB technology in various patient populations | $348,471 | 0 | 17 |
| Clinical Trial titled Absorption and Safety With Sustained Use of Relizorb Evaluation (ASSURE) Study | $161,109 | 0 | 23 |
| Fat Absorption from Enteral Formula Through an In-Line Digestive Cartridge in a Piglet Model of Short Bowel Syndrome | $111,534 | 0 | 2 |
| Retrospective Review of Relizorb Use in Patients with Severe Pancreatitis | $47,600 | 0 | 1 |
| IRB-P0042824 | $35,750 | 0 | 1 |
| Utilization of the inline digestive cartridge RELiZORB in a surgical intensive care unit | $23,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. David Recker, M.d, M.D | Internal Medicine | Libertyville, IL | $442,145 | $0 |
| Dr. Alan Muney, M.d, M.D | Pediatrics | Darien, CT | $366,434 | $0 |
| Sadeq Quraishi, M.d, M.D | Anesthesiology | Boston, MA | $78,423 | $0 |
| Mark Puder, M.d, M.D | Pediatric Surgery | Boston, MA | $56,465 | $0 |
| Dr. David Evans, M.d, M.D | Surgical Critical Care | Columbus, OH | $50,690 | $0 |
| Dr. Stephanie Abrams, M.d, M.D | Pediatric Gastroenterology | Houston, TX | $47,340 | $0 |
| Valeria Cohran, M.d, M.D | Pediatric Gastroenterology | Chicago, IL | $46,851 | $0 |
| Mr. Gareth Morris-Stiff, Mb Bch Md Mch Phd Fr, MB BCH MD MCH PHD FR | Surgery | Cleveland, OH | $39,824 | $0 |
| Dr. David Evans, Md, MD | Gynecology | Carlisle, PA | $30,453 | $0 |
| Miss. Candi Jump, D.o, D.O | Pediatric Gastroenterology | Charleston, SC | $23,945 | $0 |
| Dr. Beth Schrope, M.d, M.D | Surgery | New York, NY | $19,784 | $0 |
| Grace Carlson, Md, MD | Internal Medicine | Berkeley, CA | $19,233 | $0 |
| Meghana Sathe, M.d, M.D | Student in an Organized Health Care Education/Training Program | Dallas, TX | $17,698 | $0 |
| Pamela Hodul, Md, MD | Surgery | Tampa, FL | $16,434 | $0 |
| Mary Abigail Garcia, M.d, M.D | Pediatrics | San Diego, CA | $15,260 | $0 |
| Dr. Akash Pandey | Pediatric Gastroenterology | Orlando, FL | $15,034 | $0 |
| Dr. Steven Freedman, M.d, M.D | Gastroenterology | Boston, MA | $11,235 | $0 |
| John Stevens, Md, MD | Pediatric Pulmonology | Indianapolis, IN | $10,682 | $0 |
| Dhiren Patel, M.d, M.D | Pediatrics | St. Louis, MO | $10,625 | $0 |
| Dr. Sivan Kinberg, M.d, M.D | Pediatric Gastroenterology | New York, NY | $8,544 | $0 |
| Brenda Poindexter, Md, MD | Neonatal-Perinatal Medicine | Cincinnati, OH | $7,839 | $0 |
| Virginia Stallings, M.d, M.D | Pediatrics | Philadelphia, PA | $7,500 | $0 |
| David Evans, Md, MD | Internal Medicine | Rapid City, SD | $5,000 | $0 |
| Joseph Woolley, Do, DO | Pediatric Gastroenterology | Phoenix, AZ | $4,464 | $0 |
| Katherine Brennan | Nurse Practitioner | Chicago, IL | $3,972 | $0 |
About Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. has made $3.1M in payments to 1,370 healthcare providers, recorded across 2,644 transactions in the CMS Open Payments database. In 2024, the company paid $170,172. The top product by payment volume is RELIZORB ($3.1M).
Payments were distributed across 81 medical specialties. The top specialty by payment amount is Internal Medicine ($473,342 to 106 doctors).
Payment categories include: Food & Beverage ($110,936), Consulting ($769,760), Research ($1.4M), Travel & Lodging ($55,531).
Alcresta Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.